Cardiovascular Devices Market Size, Share and Growth Outlook, 2026

Cardiovascular Devices Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Cardiovascular Devices Market size is forecast to increase from $88.08 Billion in 2026 to $155.92 Billion in 2034 at a CAGR of 7.4% between 2026 and 2034.

The Cardiovascular Devices market report provides detailed analysis and outlook of Cardiovascular Devices segments including By Product (Diagnostic and Monitoring Devices, Surgical Devices, Therapeutic and Interventional Devices, Cardiac Rhythm Management, Prosthetic Heart Valves and Repair Devices), By Application Type (Coronary Artery Disease Management, Arrhythmia Management, Heart Failure Management, Structural and Valvular Heart Care, Peripheral Vascular Disease Interventions), By Setting (Hospitals and Hybrid Operating Rooms, Specialized Cardiac and Vascular Centers, Ambulatory Surgical Centers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Cardiovascular Devices Industry Overview

Bioabsorbable Cardiovascular Implants Advancing Peripheral Artery Disease Treatment

The cardiovascular devices industry is increasingly focused on developing next-generation implant technologies that provide temporary therapeutic support while minimizing long-term foreign material retention within the body. Abbott secured CE Mark approval for its Esprit BTK Everolimus-Eluting Resorbable Scaffold System, a specialized device designed for patients with severe below-the-knee (BTK) peripheral artery disease. The system combines drug-eluting technology with a fully resorbable scaffold architecture, providing mechanical vessel support during the critical healing period before gradually dissolving over approximately three years. Clinical evidence from the LIFE-BTK trial demonstrated strong long-term performance, with 90.3% of treated patients remaining free from target lesion reintervention after 24 months. The approval highlights growing clinical interest in bioresorbable cardiovascular devices that can restore blood flow, deliver therapeutic agents, and subsequently disappear after completing their intended function. This trend reflects the broader movement toward minimally permanent cardiovascular interventions that reduce long-term implant burden while maintaining procedural effectiveness.

Artificial Intelligence Expanding Cardiovascular Screening Capabilities

The integration of artificial intelligence into cardiovascular diagnostics is creating new opportunities for earlier disease detection and risk stratification. Anumana received FDA 510(k) clearance for its ECG-AI Pulmonary Hypertension 12-Lead algorithm, a machine learning-based Software as a Medical Device designed to identify signs of elevated mean pulmonary arterial pressure using conventional electrocardiogram data. The Class II software analyzes standard 12-lead ECG recordings from adult patients presenting with dyspnea and assists clinicians in identifying potential pulmonary hypertension before more advanced symptoms develop. A notable aspect of the technology is its regulatory clearance under a Predetermined Change Control Plan, making it one of the earliest cardiovascular artificial intelligence platforms approved within this evolving regulatory framework. The growing use of ECG-based artificial intelligence tools demonstrates the industry's commitment to leveraging existing diagnostic infrastructure while enhancing screening accuracy through advanced computational analysis.

Software-Based Cardiac Monitoring Strengthening Precision Care

Cardiovascular device innovation is increasingly extending beyond traditional hardware platforms into software-driven clinical decision support systems. SafeBeat Rx received FDA 510(k) clearance for its SafeBeat Rx App, a machine learning-enabled cardiac monitoring platform developed as a Programmable Diagnostic Computer. The application analyzes electrocardiographic signals acquired from third-party systems and automatically generates provisional measurements of critical cardiac parameters, including heart rate, RR interval variability, QT and QTc intervals, and QRS duration. In addition to automated ECG interpretation, the software incorporates specialized clinical logic designed to assist healthcare professionals in evaluating antiarrhythmic drug dosing strategies. The ability to combine advanced signal processing, machine learning, and medication management support highlights the increasing role of software-based cardiovascular devices in personalized cardiac care, remote monitoring, and precision electrophysiology management.

Cardiovascular Devices Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Cardiovascular Devices market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, Edwards Lifesciences Corporation, Johnson & Johnson MedTech, Terumo Corporation, Siemens Healthineers AG, GE HealthCare, Koninklijke Philips N.V., Getinge AB. The Cardiovascular Devices market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Cardiovascular Devices industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Cardiovascular Devices Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Cardiovascular Devices companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Cardiovascular Devices markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Cardiovascular Devices Market Competitive Benchmarking and Company Analysis

Leading companies in Cardiovascular Devices industry include- Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, Edwards Lifesciences Corporation, Johnson & Johnson MedTech, Terumo Corporation, Siemens Healthineers AG, GE HealthCare, Koninklijke Philips N.V., Getinge AB. The Cardiovascular Devices market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Cardiovascular Devices Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Cardiovascular Devices market remains one of the strongest-performing segments in the country.
The US Cardiovascular Devices Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Cardiovascular Devices market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Cardiovascular Devices industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Cardiovascular Devices markets

Canada's strong Cardiovascular Devices sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Cardiovascular Devices market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Cardiovascular Devices Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Cardiovascular Devices market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Cardiovascular Devices population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Cardiovascular Devices industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Cardiovascular Devices market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Cardiovascular Devices sales through 2034

France Cardiovascular Devices companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Cardiovascular Devices Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Cardiovascular Devices distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Cardiovascular Devices Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Cardiovascular Devices market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Cardiovascular Devices industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Cardiovascular Devices industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Cardiovascular Devices Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Cardiovascular Devices market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Cardiovascular Devices market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Cardiovascular Devices Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Cardiovascular Devices Market Segmentation

By Product
Diagnostic and Monitoring Devices
Surgical Devices
Therapeutic and Interventional Devices
Cardiac Rhythm Management
Prosthetic Heart Valves and Repair Devices
By Application Type
Coronary Artery Disease Management
Arrhythmia Management
Heart Failure Management
Structural and Valvular Heart Care
Peripheral Vascular Disease Interventions
By Setting
Hospitals and Hybrid Operating Rooms
Specialized Cardiac and Vascular Centers
Ambulatory Surgical Centers

Top Companies in Cardiovascular Devices Industry

Medtronic plc
Abbott Laboratories
Boston Scientific Corporation
Edwards Lifesciences Corporation
Johnson & Johnson MedTech
Terumo Corporation
Siemens Healthineers AG
GE HealthCare
Koninklijke Philips N.V.
Getinge AB

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025